Detalles de la búsqueda
1.
Could less be more? Accounting for fractional-dose regimens and different number of vaccine doses when measuring the impact of the RTS, S/AS01E malaria vaccine.
J Infect Dis
; 2024 Mar 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-38438123
2.
Assessing the safety, impact and effectiveness of RTS,S/AS01E malaria vaccine following its introduction in three sub-Saharan African countries: methodological approaches and study set-up.
Malar J
; 21(1): 132, 2022 Apr 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-35468801
3.
Commentary in reply to a publication on Plasmodium falciparum pre-erythrocytic stage vaccine development.
Malar J
; 19(1): 261, 2020 Jul 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-32690097
4.
RTS,S malaria vaccine could provide major public health benefits.
Lancet
; 394(10200): 735-736, 2019 08 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-31300170
5.
Efficacy of pneumococcal nontypable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in young Latin American children: A double-blind randomized controlled trial.
PLoS Med
; 11(6): e1001657, 2014 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-24892763
6.
Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial.
Lancet
; 381(9862): 214-22, 2013 Jan 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-23158882
7.
Effects of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D-conjugate vaccine on nasopharyngeal bacterial colonization in young children: a randomized controlled trial.
Clin Infect Dis
; 56(3): e30-9, 2013 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-23118268
8.
Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 Protein Vaccine.
medRxiv
; 2023 Jan 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-36523415
9.
Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, parallel, randomised, modified double-blind, placebo-controlled trial.
Lancet Respir Med
; 11(11): 975-990, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37716365
10.
Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines: a phase 3, parallel-group study.
EClinicalMedicine
; 62: 102109, 2023 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-37533419
11.
Efficacy of a monovalent (D614) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, multi-country study.
EClinicalMedicine
; 64: 102168, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37936652
12.
Immunogenicity and safety of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV) co-administered with routine childhood vaccines in Taiwan.
J Formos Med Assoc
; 111(9): 495-503, 2012 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-23021506
13.
Evaluation of the indirect impact of the 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine in a cluster-randomised trial.
PLoS One
; 17(1): e0261750, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-34986178
14.
Estimated public health impact of human rotavirus vaccine (HRV) and pneumococcal polysaccharide protein D-conjugate vaccine (PHiD-CV) on child morbidity and mortality in Gavi-supported countries.
Hum Vaccin Immunother
; 18(7): 2135916, 2022 12 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-36507685
15.
Efficacy of RTS,S/AS01E malaria vaccine administered according to different full, fractional, and delayed third or early fourth dose regimens in children aged 5-17 months in Ghana and Kenya: an open-label, phase 2b, randomised controlled trial.
Lancet Infect Dis
; 22(9): 1329-1342, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35753316
16.
Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study.
Lancet Infect Dis
; 22(5): 636-648, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35090638
17.
Primary vaccination with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in infants in Mali and Nigeria: a randomized controlled trial.
BMC Public Health
; 11: 882, 2011 Nov 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-22112189
18.
Safety and immunogenicity of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Chilean children.
Hum Vaccin
; 7(5): 511-22, 2011 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-21441782
19.
Immunogenicity, reactogenicity and safety of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Mexican infants.
Hum Vaccin
; 7(11): 1137-45, 2011 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-22048109
20.
Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1-2, dose-ranging study.
Lancet Infect Dis
; 21(9): 1257-1270, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-33887209